Will the FDA approve Sarclisa SC for multiple myeloma by July 23, 2026?

Why: Multiple independent news outlets in the supplied evidence report that the U.S. Food and Drug Administration approved a subcutaneous formulation of Sarclisa (isatuximab), marketed as Sarclisa Escena, for use in multiple myeloma. Several items explicitly state the FDA granted approval on July 10, 2026 (citing Sanofi’s press release and the pivotal IRAKLIA data); these consistent reports in the provided evidence show the approval occurred prior to the July 23, 2026 cutoff.